PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment

Phase 2Positive

AI Analysis

Summary

PridCor Therapeutics has made its first payment to Mount Sinai for the Phase 2 SHIELD study of a combination antiviral regimen for Long COVID, with study drug ordered and preliminary screening underway.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.30

Phase 2Long COVIDantiviralcombination therapyclinical trial progress

Related Companies

$STX.L $TRAX

Read the original article

Published by GlobeNewswire Pharma on September 24, 2026 11:00 AM

Read Original